Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review
Open accessThe DOI matches its Crossref record; 151 of the 151 references it cites were found in a registry or an index; 53 of the 224 sources its claims cite were checked for support.
Abstract
Background/Objectives: Incretin-based medications have transformed obesity management by enabling substantial body weight reduction. However, the rapid and pronounced loss of body mass necessitates a comprehensive, multidisciplinary approach incorporating nutritional and physical activity strategies to preserve lean mass, optimize functional outcomes, and prevent long-term complications. This narrative review provides a critical overview of this emerging clinical concern, which is expected to gain increasing relevance in the coming years. Methods: A literature review was conducted up to 31 October 2025, focusing on studies addressing nutritional, physical activity, and adjunctive interventions in adults with obesity treated with incretin-based medications. Results: Incretin-based agents induce significant weight loss, comparable to bariatric surgery, predominantly targeting adipose tissue. Nevertheless, these medications also cause rapid reductions in muscle and bone mass, often accompanied by nutrient deficiencies, which may compromise metabolic health and physical function. Tailored nutritional strategies—including hypocaloric diets enriched in protein and fiber, as well as amino acid, vitamin, and mineral supplementation—are critical to preserve lean mass and support sustained weight maintenance. Concurrently, structured, supervised physical activity, encompassing aerobics, resistance, and strength training, mitigates muscle loss and enhances functional capacity. Emerging pharmacological agents designed to promote adipose tissue reduction while preserving lean mass, as well as interventions targeting gut microbiota modulation, may represent promising adjunctive strategies to optimize long-term outcomes further. Conclusions: While incretin-based medications produce substantial weight loss, their impact on lean mass underscores the necessity of integrating personalized nutrition, supplementation, and structured exercise to preserve muscle, prevent malnutrition, and optimize long-term health and obesity outcomes.
Overview
CoChat Summary
TL;DR
Incretin-based medications produce substantial weight loss but also reduce lean mass, bone mass, and micronutrient status, requiring personalized nutrition and structured physical activity to preserve muscle and function. This narrative review synthesizes evidence from trials, supplementation studies, and bariatric-surgery paradigms to outline dietary, supplement, and exercise strategies for adults with obesity on these agents.
Key findings
- Incretin-based agents induce weight loss comparable to bariatric surgery, but a meta-analysis of RCTs found approximately 25% of total weight loss is attributable to lean mass loss, with no significant change in relative lean mass.
- In a STEP-1 DXA subset, 40% of total weight loss (6.92 kg out of 17.32 kg) was attributable to lean mass reduction, corresponding to 13.2% of baseline total lean mass; in a SURMOUNT-1 DXA substudy, tirzepatide reduced fat mass by 33.9% and lean mass by 10.9%, versus 5.3% and 2.6% with placebo.
- Nutritional strategies include hypocaloric diets enriched in protein and fiber, with suggested protein intakes of approximately 1.25–1.5 times the RDA, at least ~25–30 g protein per meal, or 1.5 g/kg fat-free mass per day; supplementation with amino acids, vitamin D, B vitamins, and minerals may be needed.
- In the Lundgren et al. RCT, combining exercise with liraglutide produced mean weight loss of 9.5 kg over one year, superior to exercise alone (4.1 kg) and liraglutide alone (6.8 kg); after treatment cessation, weight regain was 6.0 kg greater after stopping liraglutide than after stopping supervised exercise.
Methods
- Narrative review with a MEDLINE (PubMed) search conducted from February to October 2025, limited to English-language papers published within the last ten years.
- Search terms covered physical activity, nutrition, diet, supplements, lean mass loss, and lean mass preservation with anti-obesity medications.
- Eligible studies included systematic reviews, narrative reviews, meta-analyses, observational studies, RCTs, and clinical practice guidelines in adults with obesity; animal studies, participants ≤18 years, editorials, letters, case reports, book chapters, and commentaries were excluded; two authors independently assessed search and eligibility.
Limitations
- Stated: the paper notes a lack of a comprehensive, evidence-based review specifically addressing nutritional needs of patients treated with the most recent and effective anti-obesity medications, and states that official guidelines are absent.
- Stated: data are insufficient to determine the correct amount of protein needed to preserve fat-free mass after bariatric surgery, and evidence on gut microbiota changes is described as controversial with causality unresolved.
- Evident from the text: as a narrative review, it does not report a systematic protocol, risk-of-bias assessment, or quantitative synthesis; findings are drawn from heterogeneous study designs, populations, and interventions, and many nutritional/exercise recommendations are extrapolated from bariatric surgery or general obesity literature rather than from trials specifically in incretin-treated patients.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
31 Valid · 3 Not valid · 128 Not checked · 18 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Through these mechanisms, incretin-based medications promote body weight reduction primarily by targeting AT [6].”
§ Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review > 1. Introduction
What the sources say
- Partly supportedcites [6] De Fano, M., Malara, M., Vermigli, C., and Murdolo, G. (2024). Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance. Int. J. Mol. Sci., 25. sourceExperimental — accuracy not yet measured
Our copy does attribute some of the weight-loss effect to adipose-level actions — Section 6.1 (WAT/GLP-1R in adipocytes and SVF) states that supraphysiological GLP-1 RA concentrations have 'anorexigenic and lipolytic effects that, ultimately, contribute to weight loss', and Section 6.3 reports preclinical evidence that GLP-1 weight loss involves increased energy expenditure via BAT thermogenesis. However, the same Section 6.3 passage says the main mechanism is 'not only by decreasing appetite and hunger but also by increasing energy expenditure', and Section 3 ties the body-weight impact to GLP-1R in brainstem and hypothalamic appetite/regulation nuclei — so the source does not say weight reduction occurs 'primarily' by targeting AT. On the contrary, the Abstract and Section 10 frame AT as only a 'novel'/'potential' target for which the authors propose 'a potential scientific rationale', noting that adipose-specific drugs 'warrants further investigations'; the claim therefore upgrades a hedged hypothesis into a stated primary mechanism. (LLM, conf=0.78)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Semaglutide 2.4 mg weekly, evaluated in the STEP program, consistently produced 14.9–17.4% WL [19]”
§ Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review > 3. Results > 3.1. Evidence from Clinical Trials on GLP-1 RAs and Tirzepatide in Obesity: Effects on Weight Reduction and the Amelioration of Obesity-Related Organ Damage
What the sources say
- Partly supportedcites [19] Garvey, 2023, Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2): A Double-Blind, Randomised, Multicentre, Placebo-Controlled, Phase 3 Trial, Lancet sourceExperimental — accuracy not yet measured
The Discussion identifies semaglutide 2.4 mg as a treatment evaluated in STEP 2 and STEP 5 and discusses its effect on body weight. Neither the Discussion nor the Research in context passage reports the claimed 14.9–17.4% weight-loss range or establishes that it occurred consistently across the STEP program (page numbers unavailable). (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Semaglutide 2.4 mg weekly reduced major CV events in individuals with preexisting CV disease (SELECT trial) [24]”
§ Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review > 3. Results > 3.1. Evidence from Clinical Trials on GLP-1 RAs and Tirzepatide in Obesity: Effects on Weight Reduction and the Amelioration of Obesity-Related Organ Damage
What the sources say
- Supportedcites [24] Lincoff, 2023, Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes, N. Engl. J. Med. source
The Conclusions report that, in the SELECT trial, weekly subcutaneous semaglutide 2.4 mg reduced the incidence of the composite cardiovascular endpoint compared with placebo. The enrolled patients had preexisting cardiovascular disease, overweight or obesity, and no diabetes. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Additionally, other preclinical studies suggest that GLP-1 RAs may promote skeletal muscle remodeling through changes in fiber type and energy substrate utilization [12].”
§ Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review > 1. Introduction
What the sources say
- Supportedcites [12] Wu, 2022, GLP-1 regulates exercise endurance and skeletal muscle remodeling via GLP-1R/AMPK pathway, Biochim. Biophys. Acta Mol. Cell Res. source
Section 2.7.2 identifies exendin-4 as a GLP-1 receptor agonist used in the paper’s cell experiments. The Discussion reports that exendin-4 increased glucose uptake and slow-twitch fiber marker expression in myotubes, supporting the hedged claim about preclinical muscle remodeling and energy substrate use. Page numbers were unavailable in our copy. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In the SCALE Obesity and Prediabetes trial, liraglutide 3.0 mg daily combined with lifestyle intervention resulted in a mean WL of 8.4 ± 7.3 kg over 56 weeks, significantly greater than placebo (2.8 ± 6.5 kg) [18].”
§ Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review > 3. Results > 3.1. Evidence from Clinical Trials on GLP-1 RAs and Tirzepatide in Obesity: Effects on Weight Reduction and the Amelioration of Obesity-Related Organ Damage
What the sources say
- Supportedcites [18] Astrup, 2015, A Randomized, Controlled Trial of 3.0 Mg of Liraglutide in Weight Management, N. Engl. J. Med. source
The Methods (p. 1) identify the SCALE Obesity and Prediabetes trial as a 56-week comparison of once-daily 3.0 mg liraglutide and placebo, with lifestyle counseling in both groups. The Results (p. 1) report weight losses of 8.4±7.3 kg and 2.8±6.5 kg, respectively, with a significant between-group difference (P<0.001). (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
80 more claims · 12 with their cited sources checked
Create a free account to see all 180 claims and to verify the 171 references still open.
- It may state two separate claims as one. 82
- Probably not a substantial claim. 23
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent GLP-1-specific narrative consensus extends these recommendations to patients receiving incretin-based pharmacotherapy [71].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [71]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“From weeks 36 to 88, weight change was −5.5% for tirzepatide compared to −14.0% for placebo (difference −19.4%, p < 0.001).”
§ Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review > 3. Results > 3.5. PA in Obese People Treated with Incretin-Based Medications
Reported -19.4 · recomputed 8.5
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review > 3. Results > 3.1. Evidence from Clinical Trials on GLP-1 RAs and Tirzepatide in Obesity: Effects on Weight Reduction and the Amelioration of Obesity-Related Organ Damage
“Semaglutide 2.4 mg weekly, evaluated in the STEP program, consistently produced 14.9–17.4% WL [19]”
§ Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review > References
“19. Garvey W.T. Frias J.P. Jastreboff A.M. Le Roux C.W. Sattar N. Aizenberg D. Mao H. Zhang S. Ahmad N.N. Bunck M.C. Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review > 3. Results > 3.1. Evidence from Clinical Trials on GLP-1 RAs and Tirzepatide in Obesity: Effects on Weight Reduction and the Amelioration of Obesity-Related Organ Damage
“In SURMOUNT-1, tirzepatide 15 mg weekly induced a mean weight reduction of up to −20.9% at 72 weeks in individuals with obesity and without T2DM, compared with −3.1% with placebo [21].”
§ Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review > References
“21. Rubino D.M. Greenway F.L. Khalid U. O’Neil P.M. Rosenstock J. Sørrig R. Wadden T.A. Wizert A. Garvey T.W. STEP 8 Investigators Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review > 3. Results > 3.5. PA in Obese People Treated with Incretin-Based Medications
“4 diets with different percentages of protein, fat, and carbohydrates, respectively: 20, 15, and 65%; 20, 25, and 55%; 40, 15, and 45%; and 40, 25, and 35%.”
§ Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review > 3. Results > 3.5. PA in Obese People Treated with Incretin-Based Medications
“It was similar in participants assigned to a diet with 25% protein or 15% protein (3.6 and 3.0 kg, respectively; p = 0.22); the same in those assigned to a diet with 40% or 20% fat”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review > 3. Results > 3.1. Evidence from Clinical Trials on GLP-1 RAs and Tirzepatide in Obesity: Effects on Weight Reduction and the Amelioration of Obesity-Related Organ Damage
“In SURMOUNT-2, participants with obesity and T2DM experienced WL of up to −14.7% [22].”
§ Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review > References
“22. Jastreboff A.M. Aronne L.J. Ahmad N.N. Wharton S. Connery L. Alves B. Kiyosue A. Zhang S. Liu B. Bunck M.C. Tirzepatide Once Weekly for the Treatment of Obesity”
1 more finding
Create a free account to see every finding of this check.
Citations
Cites
World Health Organization 2020 guidelines on physical activity and sedentary behaviour
Bull, F. C., Al-Ansari, S. S., Biddle, S., Borodulin, K., Buman, M. P., Cardon, G., Carty, C., Chaput, J.-P., Chastin, S., Chou, R., et al. (2020) · British Journal of Sports Medicine · doi:10.1136/bjsports-2020-102955 · Cited by 11,657 · cited 1×
“To prevent weight gain and achieve health improvements, the WHO [120] and the American College of Sports Medicine [118] guidelines recommend five or more days per week of moderate-intensity PA (150–250 min/week), plus almost two days/week of strength EXE.”
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 1×
“In SURMOUNT-2, participants with obesity and T2DM experienced WL of up to − 14.7% [22].”
InfluentialSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
de Lorgeril, M., Salen, P., Martin, J.-L., Monjaud, I., Delaye, J., & Mamelle, N. (1999) · Circulation · doi:10.1161/01.cir.99.6.779 · Cited by 2,910
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
DONNELLY, J. E., BLAIR, S. N., JAKICIC, J. M., MANORE, M. M., RANKIN, J. W., & SMITH, B. K. (2009) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e3181949333 · Cited by 2,658
Weight Loss with a Low-Carbohydrate, Mediterranean, or Low-Fat Diet
Shai, I., Schwarzfuchs, D., Henkin, Y., Shahar, D. R., Witkow, S., Greenberg, I., Golan, R., Fraser, D., Bolotin, A., Vardi, H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708681 · Cited by 2,143
Lean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33102-1 · Cited by 2,095 · cited 1×
“Evidence has consistently demonstrated their benefits in individuals with obesity, including substantial WL (often exceeding the 10% WL achieved with intensive lifestyle interventions), improved quality of life (QoL), and reductions in obesity-related organ damage [7,8].”
Comparison of Weight-Loss Diets with Different Compositions of Fat, Protein, and Carbohydrates
Sacks, F. M., Bray, G. A., Carey, V. J., Smith, S. R., Ryan, D. H., Anton, S. D., McManus, K., Champagne, C. M., Bishop, L. M., Laranjo, N., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0804748 · Cited by 1,966 · cited 4×
“…in terms of WL and improved metabolic parameters are significant, their influence on eating patterns and dietary quality has not been widely reported, and an unbalanced nutritional intake accompanied by a calorie deficit can lead to macro/micronutrient deficiencies and loss of LM [59,63,73,152].”
InfluentialDefinition and diagnostic criteria of clinical obesity
Rubino, F., Cummings, D. E., Eckel, R. H., Cohen, R. V., Wilding, J. P. H., Brown, W. A., Stanford, F. C., Batterham, R. L., Farooqi, I. S., Farpour-Lambert, N. J., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00316-4 · Cited by 1,811
Cited by
Al-Awadi, A. A., Alroudhan, D., Alsaeed, D., Almarshad, B. W., Alshehabi, D. H., Al‐Lahou, B., Mashankar, A., Al‐Ozairi, E., & Gray, S. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-116911 · Cited by 16
Zambrano-Villacres, R., Campuzano-Donoso, M., Reytor-González, C., Rossetti, G., Cobellis, L., Cobellis, F., Pilone, V., Simancas‐Racines, D., & Schiavo, L. (2026) · Nutrients · doi:10.3390/nu18111751 · Cited by 8
Dziewierz, A., & Siudak, Z. (2026) · Nutrients · doi:10.3390/nu18111761 · Cited by 3
“Recent GLP-1-specific narrative consensus extends these recommendations to patients receiving incretin-based pharmacotherapy [71].”
Olumuyide, E. O., Ariel, K., & Aneni, E. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02143-x · Cited by 1
Mallardo, M., Messina, A., Monda, V., Marra, M. L., Monda, A., Allocca, S., Casillo, M., Maio, G. D., Perrone, P., Daniele, A., et al. (2026) · Nutrients · doi:10.3390/nu18172748 · Cited by 1
Metadata
- Authors
- Barana, L., De Fano, M., Cavallo, M., Manco, M., Prete, D., Fanelli, C. G., Porcellati, F., & Pippi, R.
- Affiliations
- Ospedale degli Infermi (IT)
- Endocrine and Metabolic Sciences Section, Department of Medicine and Surgery, University of Perugia, 06132 Perugia, Italy
- Azienda Ospedaliera S.Maria (IT)
- University of Perugia (IT)
- Corresponding author
- Cavallo, Massimiliano
- Prete, Deborah
- ORCID
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2025-12-31
- Volume
- 18
- Issue
- 1
- Pages
- 131
- ISSN
- 2072-6643 (ISSN-L)
- PMC
- PMC12787956
- OpenAlex
- W7117762628
- Cited by
- 13
- References
- 144
- Citations by year
- 2026: 13
- FWCI
- 1.76
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nutrients (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- obesity, weight loss, lean mass preservation, muscle mass loss, bone loss, malnutrition, protein supplementation, hypocaloric diet, amino acid supplementation, vitamin and mineral supplementation, physical activity, resistance training, gut microbiota, adipose tissue reduction, weight maintenance
- MeSH terms
- Body Composition, Humans, Obesity, Weight Loss, Exercise, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
